Microbot Medical Inc. has been awarded its first Japanese patent for core LIBERTY Endovascular Robotic System technology, such as a compact robotic device for driving and manipulating the movement of at least one elongate surgical tool. The company also received patents in the U.S., China, and Israel over the summer and early fall.

The company secured U.S. Food and Drug Administration (FDA) clearance for the LIBERTY two months ago, and has accelerated its commercial launch plans as it targets an estimated 2.5 million peripheral endovascular procedures performed in the United States annually. As Microbot Medical evaluates other future global markets that have historically accepted FDA cleared devices, the successful implementation of its global IP strategy is expected to protect and allow it to monetize its technology.

“Our initial focus is on the U.S. market, however, certain markets such as Japan, represent attractive and strategically important markets for the LIBERTY System,” Microbot Medical Chairman/President/CEO Harel Gadot said. “Building on our recent FDA clearance of LIBERTY, we are evaluating opportunities to expand into other global markets that have traditionally taken FDA clearance into consideration to potentially expedite local approval and adoption.”

Microbot Medical Inc. is a breakthrough medical device company developing advanced robotic technology. Microbot’s LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. The company boasts a strong intellectual property portfolio.